DelveInsight's “Persistent Corneal Epithelial Defects Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Persistent Corneal Epithelial Defects ...

Please provide your email address to receive an email when new articles are posted on . Eyevance Pharmaceuticals has acquired worldwide licensing rights to Nexagon, a 30-base antisense oligomer ...

Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Persistent Epithelial Defect Market - A Global and Regional Analysis: Focus on End User and Region, 2025-2035" has been added to ResearchAndMarkets.com's ...

Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...

Kala Pharmaceuticals, a biopharmaceutical company specializing in therapies for rare eye diseases, has a promising drug, KPI-012, in its pipeline for treating Persistent Corneal Epithelial Defect ...

There were 35 eyes of 33 patients, with a mean age of 68.2±19.5 years (range: 17–99 years). There were 25 men and 8 women. Median follow-up was 110 days (mean: 164.6 days; range: 30–960 days). The ...

Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...

Kala Pharmaceuticals (KALA) is a great speculative biotech play to look into. The reason why I state that is because it received IND clearance from the FDA to initiate a phase 2b study, using its ...

Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness. A new study provides exciting evidence ...